Company / SG&A Expense
KIORA PHARMACEUTICALS INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$5.5M
FY2025
5-year range
$4.4M / $5.5M
FY2021-FY2025
Trend
+18.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 3 consecutive years, from $4M in FY2020 to $6M in FY2025.
Based on SEC 10-K filings.
$6M in FY2025 with a 5-year CAGR of +4.7%.
Increased from $5M to $6M over the past 4 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +4.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- KIORA PHARMACEUTICALS INC's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +4.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 18.9% year-over-year.
- Peak sg&a expense was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score -5.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.5M | +18.9% |
| FY2024 | $4.7M | +0.1% |
| FY2021 | $4.7M | +5.7% |
| FY2020 | $4.4M | -0.8% |
| FY2019 | $4.4M | -4.2% |
| FY2018 | $4.6M | -17.1% |
| FY2017 | $5.6M | +41.2% |
| FY2016 | $4.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026